Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study was designed to check the efficacy of a new oral medical drug treatment, namely Cabergoline, for the treatment of Cushing Disease due to pituitary adenoma.

Background: Cabergoline is a Dopamine 2 receptor agonist. Corticotroph adenoma has shown to have the D2 receptor in in vitro studies.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seth Gordhandas Sunderdas Medical College
• Treatments: Cabergoline

Criteria

Inclusion Criteria:

• Patient with Cushing's disease uncured biochemically after pituitary surgery with adenoma on histopathology

Exclusion Criteria:

• Patient's intolerance to drug or known sensitivity to ergot derivatives

• Pregnancy, lactation or female wishing to be pregnant

• Any serious medical illness

• Patient on any drugs known to have an interaction with cabergoline including antihypertensives like reserpine and methyl dopa, neuroleptics, metoclopramide, etc